Condition: Prostate Cancer · Sponsor: Philogen S.p.A.
The aim of this study is to assess the safety and dosimetry of imaging with \[68Ga\]Ga-OncoACP3 in patients with prostate cancer.
This description comes directly from the study's public registry record.
Jacqueline Mock · +41 43 544 88 02 · regulatory@philogen.com
Francesco Colognese · +39 0577 17 816 · regulatory@philogen.com
Always discuss trial participation with your own doctor first.
| Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII | Bergamo, Bergamo, Italy | Recruiting |
| Ospedale San Raffaele S.r.l. | Milan, Milano, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07600554